Post-earnings recap
Reported
Tue, Feb 17, 2026
EPS actual
$1.70
EPS est.
$1.62
EPS surprise
+4.94%
1-day move
+4.12%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Krystal Biotech's earnings report shows a positive surprise in EPS, which contributed to a 4.12% increase in stock price. The management's optimistic tone suggests confidence in their ongoing projects, even without specific revenue figures or future guidance. Investors may view the EPS beat as a sign of strong performance amidst uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.70 | N/A | +4.94% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. They did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering innovative solutions to our patients.